sphingotec announced today that the results of two studies examining the association between proenkephalin (pro-ENK) and incident breast cancer were published online in the Journal of Clinical Oncology. The studies, which were conducted by researchers at Skåne University Hospital in Malmö, Sweden and together encompass almost 3,500 subjects, demonstrated a strong association between low plasma concentration of the opioid precursor peptide pro-ENK and increased breast cancer risk in middle-aged and post-menopausal women independent from other possible risk factors.
Although experimental studies have established that enkephalins and related opioid hormones can inhibit the growth of cancer cells, these are the first studies to investigate whether plasma concentration of pro-ENK can predict near-term breast cancer risk in healthy women. The strong association between concentrations of pro-ENK and incident breast cancer found during these studies indicates that pro-ENK is a viable tool for predicting breast cancer risk.
The results represent a potential breakthrough in helping women without a known family history of breast cancer understand their own risk. Current tools such as the GAIL risk score are helpful, but the parameters included in the score are non-modifiable, have only weak prognostic power and do not address an individual’s risk. And while mammography is effective at detecting early stage breast cancer, there is ongoing concern about over-diagnosis and missed cases. There is a great need for biomarkers that can identify women at highest risk so that appropriate interventional measures can be taken to prevent clinical manifestation of life-threatening breast cancer.
“Our goal is to prevent deaths related to breast cancer,” said Dr. Andreas Bergmann, founder and CEO for sphingotec. “We have now identified two promising biomarkers to achieve this goal: proneurotensin* (pro-NT) and proenkephalin, which have been demonstrated now in two independent cohorts to predict risk in healthy women. The results of these studies imply great promise for the future of breast cancer prevention. We believe these findings will aid in helping women better understand their breast cancer risk so they can take the appropriate measures for preventing this devastating disease.”
To conduct the first study, Melander et al. measured pro-ENK in fasting plasma from 1,929 healthy women with a mean age of 59 years old participating in the Malmö Diet and Cancer Study (MDCS) and used Cox proportional hazards models to relate pro-ENK to incidence of breast cancer during 15 years of follow up. In the second study, using a case-control design, they sampled 1,569 women from the Malmö Preventive Project with a mean age of 70 years old and used multivariate adjusted logistic regression models to relate pro-ENK and to risk of breast cancer during the observation period.
Results of this study appear online in the Journal of Clinical Oncology.
*Melander et al. JAMA. 2012;308(14):1469-1475
Authors: Olle Melander, Marju Melander, Jonas Manjer, Peter Almgren, Peter Nilsson, Gunnar Engström, Bo Hedblad, Signe Borquist, Ute Kilger, Jennifer Suhr, Oliver Hartmann, Joachim Struck, Andreas Bergmann and Mattias Belting
Sphingotec will present the lastest research results at this years AKI & CRRT 2016 that underline the diagnostic value of penKid, both for the prediction of acute kidney dysfunction in critically ill patients and for the prediction of chronic kidney diesases in the general population. The AKI & CRRT is one of the major International Conferences on Acute Care Nephrology and will be held between February 16-19, 2016 in San Diego, California (USA).
Besides Prof. Alan Maisel, from UC San Diego, who will give an extensive overview about sphingotec’s kidney biomarker penKid (LUNCH SYMPOSIUM A – 2016/02/17 11:30am-1:00pm), Dr. Joachim Struck, Head of Research & Development at sphingotec, will present the latest results from several international clinical studies that sphingotec conducted in collaboration with internally renown scientists from UMC Groningen (Netherlands), Lund University Malmö (Sweden), University Hospital Saint Louis – Lariboisière Paris (France) and IRCCS Milan (Italy).
Biomarkers of Acute Kidney Injury and Outcome in Critically Ill Patients
Matthieu Legrand 1, Joachim Struck 2, Alain Cariou 1, Nicolas Deye 1, Bertrand Guidet 1, Samir Jaber 1, Marc Leone 1, Antoine Vieillard Baron 1, Etienne Gayat 1, Alexandre Mebazaa 1 (1) Department of Anesthesiology and Intensive Care, Saint Louis – Lariboisière – Fernand Widal University Hospital, AP-HP, Paris, France, (2) sphingotec GmbH, Hennigsdorf, Germany
High Level of Plasma Pro-Enkephalin (penKid) in the General Population Predicts Deterioration of Kidney Function and Incidence of Chronic Kidney Disease
Christina-Alexandra Schulz 1, Ulrika Ericson 1, Peter Almgren 2, George Hindy 1, Peter M Nilsson 3, Joachim Struck 4, Andreas Bergmann 4, Olle Melander 5, Marju Orho-Melander 1 (1) Department of Clinical Sciences, Diabetes and Cardiovascular Disease – Genetic Epidemiology, University Hospital Malmo Clinical Research Center, Lund University, Malmo, S, (2) Department of Clinical Sciences, Diabetes and Endocrinology, University Hospital Malmo Clinical Research Center, Lund University, Malmo, Sweden, (3) Department of Clinical Sciences, University Hospital Malmo Clinical Research Center, Lund University, Malmo, Sweden, (4) sphingotec GmbH, Hennigsdorf, Germany, (5) Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, University Hospital Malmo Clinical Research Center, Lund University, Malmo, Sweden
Plasma Pro-Enkephalin (penKid) and Renal Impairment in Severe Sepsis and Septic Shock: Data from the ALBIOS Trial Serge Masson 1, Pietro Caironi 2, Joachim Struck 3, Sandra Ferraris 4, Valentina Bellato 5, Oliver Hartmann 3, Andreas Bergmann 3, Luciano Gattinoni 2, Antonio Pesenti 2, Roberto Latini 1 (1) IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, Milan Italy, (2) Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, Università degli Studi di Milano, e Dipart, (3) sphingotec GmbH, Hennigsdorf, Germany, (4) U.O. di Anestesia e Rianimazione, Ospedale di Treviglio-Caravaggio, Treviglio, Italy, (5)U.O. Anestesia e Terapia Intensiva Generale, Istituto Clinico Humanitas, Rozzano, Italy
Plasma Pro-Enkephalin and Poor Long-Term Outcome in Renal Transplant Recipients Lyanne M Kieneker 1, Joachim Struck 2, Ron T Gansevoort 1, Michel M Joosten 1, Rodolf A de Boer 3, Oliver Hartmann 2, Andreas Bergmann 2, Stephan J Bakker 1 (1) Internal Medicine, Nephrology, UMC Groningen, Netherlands, (2) sphingotec GmbH, Hennigsdorf, Germany, (3) Cardiology, UMC Groningen, Netherlands The Association of
Plasma Pro-Enkephalin with Renal Function Decline Lyanne M Kieneker 1, Oliver Hartmann 2, Joachim Struck 2, Ron T Gansevoort 1, Michel M Joosten 1, Rudof A de Boer 3, Andreas Bergmann 2, Stephan J Bakker 1 (1) Internal Medicine, Nephrology, UMC Groningen, Netherlands, (2) sphingotec GmbH, Hennigsdorf, Germany, (3) Cardiology, UMC Groningen, Netherlands
The final conference program can be downloded here.
The AKI & CRRT 2016 held between 16.-19. Februar 2016 in San Diego (USA) is one of the major International Conferences on Acute Care Nephrology. sphingotec is on site, in order to discuss the lastest research on early prediction of kidney dysfunction with key opinion leaders in acute and intensive care medicine.
In this context, Prof. Alan Maisel, from the UC San Diego, will present penKid, sphingotec’s biomarker for kidney dysfunction, to a large audience of national and international experts in the session „New Kids on the Block: Emerging Biomarkers in AKI, CKD and Cardiorenal Syndrome“ (LUNCH SYMPOSIUM A – 2016/02/17 11:30am-1:00pm).
The final Conference Program can be downloaded here.